Product Development Funding Programs – Cancer Prevention and Research Institute of Texas (CPRIT)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

CPRIT provides flexible, non-dilutive funding to support the development and commercialization of innovative cancer technologies. Through four distinct programs—SEED, TDDC, TTC, and TNTC—CPRIT funds companies across the full lifecycle, from early-stage discovery to late-stage clinical development. Preliminary applications are due April 16, 2026, with full applications due July 9, 2026.

How much funding would I receive?

Funding varies by program:

• SEED Awards: Up to ~$3 million (early-stage)

• TDDC, TTC, TNTC: No fixed cap; funding is flexible and negotiated based on project scope

CPRIT allocates approximately $70 million annually for company investments and distributes funding through milestone-based contracts tied to project progress

What could I use the funding for?

Funding supports research and development of technologies for the prevention, detection, diagnosis, monitoring, and treatment of cancer.

Common use cases include:

• Artificial intelligence and bioinformatics

• Therapeutics (drugs, biologics, cell therapies)

• Diagnostics and medical devices

• Manufacturing and biomanufacturing

• Clinical validation and trials

• Sample quality improvement and research tools

Which CPRIT Program is right for me?

CPRIT offers four programs designed for different stages and technology types:

SEED Awards (Earliest Stage)

• Focus: Preclinical and company formation

• Stage: Discovery → proof-of-concept

• Goal: De-risk early science and make the company investable

• Funding: Up to ~$3M

TDDC (Texas Diagnostic & Device Company Awards)

• Focus: Diagnostics and medical devices

• Stage: Late-stage development (near regulatory submission)

• Goal: Advance toward commercialization and market entry

TTC (Texas Therapeutics Company Awards)

• Focus: Therapeutics (drugs, biologics, cell therapies)

• Stage: IND-enabling through clinical development

• Goal: Advance clinical programs and regulatory approval

TNTC (Texas New Technologies Company Awards)

• Focus: Emerging and non-traditional technologies

• Stage: Varies

• Examples: AI, platforms, research tools, enabling technologies

• Goal: Support innovations that do not fit neatly into therapeutics or devices

What is the application process?

All CPRIT programs follow the same two-stage, competitive process:

Stage 1: Preliminary Application (Initial Screening)
Applicants submit:

• Abstract

• Executive summary (≤2 pages)

• Slide deck (≤16 slides)

• Project aims and budget

Applications are reviewed for scientific merit and alignment with CPRIT priorities. Only top applicants are invited to proceed.

Stage 2: Full Application (Deep Diligence)
Invited companies submit:

• Integrated product development plan (technical, clinical, regulatory)

• Full business plan (market, competition, commercialization, financials, IP)

• Timeline and milestones

• Management team and execution plan

Applicants present to an expert panel and undergo due diligence before final selection.

Final Decision Process

• Scientific and product review

• Due diligence

• Program Integration Committee review

• Final approval by CPRIT Oversight Committee

Funding is awarded via milestone-based contracts tied to performance.

What is the timeline to apply and when would I receive funding?

• Preliminary Application Opens: April 7, 2026

• Preliminary Application Deadline: April 16, 2026

• Full Application Invitation: June 2026

• Full Application Deadline: July 9, 2026

• Award Period: September 1, 2026 – August 31, 2027

Funding is deployed over multiple years based on milestone completion.

Where does this funding come from?

Funding is provided by CPRIT through $6 billion in Texas taxpayer-backed general obligation bonds dedicated to cancer research and commercialization.

Who is eligible to apply?

Applicants must be:

• Texas-based, for-profit companies (or willing to relocate)

• Able to meet Texas presence requirements (e.g., HQ, personnel, manufacturing, or clinical activity in Texas)

• Compliant with CPRIT eligibility rules

What companies and projects are likely to win?

• Address a significant unmet medical need

• Demonstrate strong technical validation

• Show a clear path to commercialization

• Have an experienced management team

• Present a credible regulatory and development strategy

Are there any restrictions I should know about?

• Must maintain a business presence in Texas or be willing to relocate to Texas upon selection for award

• Matching funds are required

• Indirect costs capped at ~5%

• Travel expenses are not reimbursable (can count as matching funds)

• Funding is milestone-based with reporting requirements

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

1. Triple your likelihood of success through proven strategy and insider-aligned proposal development

2. Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

3. Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($20,000 + 5%) available (Only $5,000 for preliminary application).

Additional Resources

Review the solicitation here.